



Registered & Corporate Office:
AMANTA HEALTHCARE LIMITED
8th Floor, Shaligram Corporates, CJ Marg,
Ambli, Ahmedabad-380058, Gujarat, INDIA.
Tel.: 079 – 67777600
Email: info@amanta.co.in
Website: www.amanta.co.in

CIN: L24139GJ1994PLC023944

May 19, 2026

To, Sr. General Manager Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Scrip Code: 544502	To, Sr. General Manager National Stock Exchange of India Limited Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai – 400 051. Trading Symbol: AMANTA
--	---

Dear Sir/ Madam,

Sub: Investors Presentation on Financial Results of the Company for the quarter and year ended March 31, 2026

Please find enclosed the Investors Presentation on Financial Results of the Company for the quarter and year ended March 31, 2026.

You are requested to take the same on your records.

Thanking you.

Yours sincerely,

For AMANTA HEALTHCARE LIMITED

NIKHITA DINODIA
Company Secretary & Compliance Officer

Encl.: As above



Amanta Healthcare Limited

Q4 & FY26 Investor Presentation

Disclaimer

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Amanta Healthcare Ltd.** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.



NICHE PHARMACEUTICAL COMPANY

30+ Years of *Sterile Liquids* Legacy

Integrated

LVPs & SVPs manufacturer

SteriPort

Established generic brand

Widely used in hospitals

Critical medications


Advanced tech

ABFS & ISBM across 6 therapeutic segments

OPERATIONAL METRICS



FINANCIAL METRICS



THERAPEUTIC SEGMENTS





Built to scale – Amanta’s differentiated business model




RM Sourcing

Key materials Sourced

27.5% LDPE	18.5% TWO PORT CLOSURE SYSTEM	12.5% POLYPROPYLENE
---------------	--	------------------------

Geographical concentration of Plastic Purchase




Top 10 suppliers account for 76% of materials consumed



Manufacturing Capabilities

Manufacturing facility in Gujarat spanning 66,852 sq. mts

LVP 4 lines	SVP 3 lines
Total Capacity : 12.28 crore	Total Capacity : 20.91 crore
2 Lines : Conventional Single port bottles	2 Lines : ABFS
2 Lines : Steriport with ISBM technology	1 Line : Conventional 3-piece container



3 Channel Distribution

Robust sales and distribution team with strong presence across the globe

Branded products domestically through 320+ distributors

Exports to emerging and semi-regulated markets

Product Partnering

Portfolio expansion in markets such as UK, Latin America, South East Asia & Africa



Types of IV Fluids :

Dextrose, Normal Saline, Combination Of Dextrose Normal Saline, Ringer Lactate, Electrolytes.

Packaging Of Product :


Single Port Container, Two Port Container

Fill Volume Options :

100ml, 250ml, 500ml, 1000ml.

Innovative Technology :

Amanta manufactures SteriPort bottles for IV fluids using ISBM Technology, with polypropylene as the raw material



Fluid Therapy

Notable Formulations :

Ciprofloxacin, Metronidazole, Ofloxacin, Paracetamol, Fluconazole.

Packaging Options :


- Large Volume Parenterals (LVPs)
- Small Volume Parenterals (SVPs)

Fill Volume Range :

2ml to 100ml

Technology :

Aseptic Blow-Fill- Seal (ABFS) & Injection Stretch Blow Moulding (ISBM) technology



Formulations

Diluent Product Overview :


- Plain Water for Injection (WFI)
- Normal Saline

Diluents Pack Sizes :

Offered in 5 ml & 10 ml


Injectables Portfolio Key Products :

Lidocaine, Potassium Chloride, Magnesium Sulphate, Calcium Chloride, Calcium Gluconate



Diluents & Injectables

Revenue share across all categories



Applications :


Treatment for Infections, Glaucoma, Inflammation.

Dosage Forms :

5ml & 10 ml

Packaging Options :

- Form Fill Seal (FFS) Pack
- Three-Piece Conventional Pack



■ Ophthalmic

Applications :

Administered through nebulisers for the treatment of lungs affected by Asthma or Bronchiectasis

Dosage Form :


Available in 2.5 ml

Key Products :

Respiratory Suspension

Budesonide, Salbutamol

- Salbutamol & Ipratropium Bromide
 - Levosalbutamol
- Levosalbutamol & Ipratropium



■ Respiratory Solutions

Product Types :


OTC Eye Lubricants
Wound Cleaning Solutions

Dosage Forms :

Available in 5 ml, 10 ml & 20 ml

Product :

- Sodium Chloride Eye Wash
- Wound Cleaning



■ Irrigation Solutions

Driving *Success*

47 Products

120 Countries

30+ Years



 **PRODUCTS & MARKETS**

Well-established Pharma Manufacturer

Six therapeutic segments and container systems. 47 products registered in 120 countries across LVPs and SVPs.


47 Products

 **DISTRIBUTION**

Wide Domestic & Global Network

Pan-India network of 320 distributors, 96 sales staff, and integrated IT systems across 21 export markets.

320 Distributors

 **INFRASTRUCTURE**

Scaled-up Manufacturing Capabilities

Gujarat facility spanning 66,852 sq. meters with Aseptic BFS and ISBM technologies. ISO & WHO-GMP certified.

66,852 sq.m

 **HUMAN CAPITAL**

Leadership & Skilled Workforce

Management team with 30+ years of experience, supported by 506 employees (≈1,700 with contract workers).

506 Employees



Differentiated Manufacturing Technologies to Market End Product



First to bring ISBM technology to India

TECHNOLOGY 01

Aseptic Blow Fill Seal (ABFS)

Technology

FFS (Form-Fill-Seal) used for IV fluid packaging.

Process

Bottles formed, filled and sealed in one automated step — zero human contact.

Features

Nitrogen purging for sensitive formulations like paracetamol.

Capacity

Produces 8 bottles in ~15 seconds.

TECHNOLOGY 02

Injection Stretch-Blow Moulding (ISBM)

Technology

Multiple-stage operation using preforms, unlike FFS.

Process

Preforms stretched and blown into PP bottles from 100 ml upward.

Filling

Bottles air washed, WFI washed, dried, filled and sealed.

Advantage

50–60% domestic market share, commanding premium pricing.

SUPPORT SYSTEM

F&D Capability

In - house Product development

Dedicated team for Regulatory Affairs.

PIC complaint facility



THREE STRATEGIC PILLARS

01

MARKET DEPTH

Wallet Share Expansion

Complex dosages and niche molecules across anti-infectives, respiratory care, and ophthalmics.

02

MANUFACTURING

Capacity Expansion

Scaling high-margin SteriPort and SVP capacities by 5.39 Cr and 10.78 Cr units respectively.

COMMISSIONING
Q1FY27 & Q4FY27

03

EFFICIENCY

Green Energy & Cost Optimisation

Solar captive power plant of 10.8 MW generating an expected annual saving of ₹9 Cr.

SOLAR PLANT
10.8 MW

Growth levers aimed for
Next Two Years

Revenue CAGR 20%+ | EBITDA Margin 25%+



Our Flagship Product



First in India to shift from BFS → ISBM

Dominant in PP IV bottle segment

6.62 Cr Bottles Capacity	91% Capacity Utilization	44% Revenue Contribution	100–1000ml Full Range In-house
------------------------------------	------------------------------------	------------------------------------	--

- ✓ Oncology
- ✓ Critical Care
- ✓ Pediatrics
- ✓ Intensive Care
- ✓ Anesthesia

MATERIAL **ISBM-Ready**

Random Co-Polymer PP

- Superior tensile strength
- Barrier properties
- >121.1°C sterilization

STERILIZATION **WHO-GMP**

SAL 10⁻⁶ Certified


- Transparency
- > 121.1°C Sterilization

DESIGN **Hospital Grade**

Closed System

- Two Port System; One for IV Syringe & One for Injection
- Temper Evident Closure System
- Preferred by Intensive Care

SteriPort (LVP) Expansion in Capacity (In Cr.)



Expected to generate incremental revenue of 110-120 Cr per year with EBITDA margin expanding by 3-4%.

LVP Lines	Installed Capacity (Cr Bottles).
Line 1	2.53
Line 2	3.12
SteriPort	
Line 1	5.15
Line 2	1.47




High Margin Product

SVP *(Ready to move up the value chain)*

- An export centric segment
- Capacity tripled in 2008
- Incremental capacity is targeted at growing Inhalation Solution portfolio (Respules), OTC portfolio and Preservative Free unit doses.
- Contributed ~20% of the revenue in FY26. The segment operates at EBITDA margins of 22 – 27%.

SVP Expansion in Capacity (Qty Cr.)






Location:

Block No: 872B, 873A, 874, 876 and 877 village Hariyala, District Kheda Gujarat, India



Certifications & Compliance:

- ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, ISO 45001:2018, WHO-GMP certified.
- Certified by the Food & Drugs Control Administration Gujarat.
- Conformity with WHO guidelines and GMP for formulations from Cambodia, Sudan, Philippines, and Zimbabwe.




Production Capabilities:

- Injections
- Sterile Liquids
- Eye Care Products
- Respiratory Solutions





Utilization % across each Parenteral




FY26	Installed capacity (Units in crs)
LVP (excluding SteriPort)	5.7
SVP	20.9
SteriPort	6.6

Current Utilization of 96% - indicating strong demand visibility and efficient asset utilization.

Stable installed capacity combined with rising actual production highlights the company's operational discipline

Capex to drive future growth





Capex & Robust product pipeline to drive future growth

- Capacity Scale-up across all the lines
- Transition to Renewable Energy / Solar Power Integration
- Accelerated Product Pipeline / New Product Rollouts



De-leveraging in overdrive: Debt-to-Equity ratio reduced by over 70% since FY23

- Reduced total borrowings by over INR 30 Cr, primarily through the full repayment of all outstanding Non-Convertible Debentures (NCDs).





Captive Solar Power Plant 10.8 MW

Under implementation to structurally lower power costs

TOTAL PROJECT COST

INR 34.8 Cr

Largely debt-funded

ANNUAL SAVINGS

INR 9 Cr

Power cost reduction

PAYBACK PERIOD

3.6 yrs

Pre-interest basis

Key Watch Points



Q1 FY27 commissioning

Benefits to be reflected FY27 onwards



INR 5.8 Cr equity outlay

Balance funded via term loan



EBITDA margin improvement

From INR 9 Cr annual power cost savings



Stronger ESG profile

Lower carbon footprint, cleaner energy mix



Mr. Bhavesh Patel
Chairman and Managing Director
30+ Years Of Experience



Mr. Pratik Gandhi
Non-Executive Director
10+ Years Of Experience



Mr. Nimesh Patel
Non-Executive Director
3+ Years Of Experience

Bhavesh Patel is the Chairman and Managing Director and a promoter of the Company, associated since its incorporation. With over 30 years of industry experience, he is a Mechanical Engineer and a graduate in Finance.

Pratik Gandhi is the Non-Executive Director of our Company. With over 10 years of teaching experience, he is a qualified cost and work accountant.

Nimesh Patel is the Non-Executive and Non-Independent Director of our company. He is a graduate of the Wharton School with a degree of Science in Economics.



Ms. Anjali Choksi
Independent Director
15+ Years Of Experience



Mr. Kshitij Patel
Independent Director
25+ Years Of Experience



Mr. Nitin Jain
Independent Director
20+ Years Of Experience

Anjali Choksi is an Independent Director of the Company. She is a qualified chartered accountant & holds Ph.D in philosophy. Over 15 years of experience as a partner at DNV & Co. – CA firm.


Kshitij Patel is the Independent and Non-Executive Director of the company. A qualified chartered accountant & a partner of the firm Manubhai & Shah LLP.

Nitin Jain is an Independent Director of our Company. Having over 20 yrs experience as an Investment Banker & a partner of the firm Fulcrum Advisors. He is a graduate in Chemical Engineering & Postgraduate in management from IIM – Bengaluru.




Quarter Performance


Revenue



EBITDA and Margins (%)




PAT and Margins (%)




FY26 Performance


Revenue



EBITDA and Margins (%)



PAT and Margins (%)





Profitability increased by 42% in FY26 on YoY basis



Sustained revenue trajectory:

Q4FY26 revenue stood at INR 77 cr, registering a 7% YoY growth, while FY26 revenue reached INR 288 cr, marking a 5% YoY increase, reflecting consistent growth.



Operational discipline sustains EBITDA margins:

EBITDA for Q4FY26 came in at INR 17 cr with margins at 21%, while FY26 EBITDA increased 6.06% YoY to INR 63 cr, with margins improving YoY to 22%, highlighting effective cost control and operational efficiency.



Profitability strengthens on robust execution:

Net Profit for Q4FY26 rose to INR 5.5 cr, up 28% YoY, while FY26 PAT grew 42% YoY to INR 15 cr, underscoring strong profitability momentum led by decreasing in finance cost.



Improving earnings quality reflected in margins:

Q4FY26 PAT margin stood at 7%, while FY26 PAT margin stood at 5% compared to 4% for FY25 driven by operating leverage and margin normalization.



Revenue Breakdown – Annual performance

(Figures in Rs. crs)

Revenue from operations	FY26	FY25	FY24	FY23
Revenue from contract with customers :				
Sale of products	282	267	272	253
Sale of services	3	5	6	5
Sub- total	284	272	278	258
Other operating revenue :				
Scrap sales	2	1	1	1
Export incentives	2	1	0	1
Total	288	275	280	259

Particulars	FY26	FY25	FY24	FY23
Revenues	288	275	280	259
Other Income	3	1	1	4
Total Income	291	276	282	263
Cost of materials consumed	97	101	86	101
Purchases of stock-in-trade	11	12	2	1
Changes in inventories of finished goods, work-in-process and stock-in-trade	(11)	(20)	17	53
Employee costs	43	36	33	32
Other expenses	88	85	85	73
Total Expenditure	228	215	223	206
EBITDA	63	61	59	56
Finance Costs	21	28	34	35
Depreciation and Amortization Expenses	19	18	20	18
Exceptional Items	3	-	-	-
PBT	21	15	5	3
Tax	6	4	2	5
PAT	15	11	4	(2)
Restated Other Comprehensive Income/(loss) for the period, net of tax	1	0	0	0
Restated Total Comprehensive Income/(loss) for the period	14	10	3	(2)



Balance Sheet

Assets	FY26	FY25	FY24	FY23
Non-Current Assets				
Property, plant and equipment	197	208	223	229
Capital work-in-progress	82	7	-	-
Right-of-use assets	9	9	5	9
Intangible assets	1	1	-	-
Non-Current Financial Assets	16	9	5	5
Non current tax assets(Net)	0	0	-	-
Other Non-Current Assets	15	11	1	0
Total Non-Current Assets	320	244	234	243
Current Assets				
Inventories	83	73	60	69
Trade receivables	43	50	48	54
Cash & Cash Equivalents	81	0	2	0
Bank Balance Other Than Cash	12	3	3	4
Other Financial Assets	0	-	-	-
Loans	1	1	0	0
Other Current Assets	19	11	6	5
Total Current Assets	238	138	118	131
Total Assets	558	382	352	374

Equities & Liabilities	FY26	FY25	FY24	FY23
Equity share capital	39	29	27	27
Other Equity	181	68	40	36
Net Worth	220	96	66	63
Non-Current Liabilities				
Non-Current Borrowings	162	132	149	176
Lease Liabilities	8	8	5	7
Deferred Tax Liabilities (Net)	27	30	30	32
Total Non-Current Liabilities	197	170	184	214
Current Liabilities				
Current Borrowings	72	63	56	40
Lease Liabilities	2	1	-	3
Current Tax Liabilities(Net)	3	1	1	3
Trade Payables	36	31	25	36
Provisions	11	8	7	6
Other Current Liabilities	1	2	2	1
Other Financial Liabilities	7	4	3	3
Contract Liabilities	9	6	8	6
Total Current Liabilities	141	115	102	97
Total Equity & Liabilities	558	382	352	374



Cash Flow Statement

(Figures in Rs. crs)

Particulars	FY26	FY25	FY24	FY23
Cashflow from Operating Activities	48	47	58	43
Cashflow from Investing Activities	(94)	(25)	(10)	(7)
Cashflow from Financing Activities	126	(24)	(46)	(42)
Cash and Cash Equivalents as at end of period/Year	81	0.2	1.5	0.1

Annexure

Our Product Categories -



Fluid Therapy - (IV Fluid)



Types of IV Fluids :

- Dextrose
- Normal Saline
- Combination Of Dextrose Normal Saline
- Ringer Lactate
- Electrolytes

Packaging Of Product :

- Single Port container
- Two Port container

Fill Volume Options :

- 100ml
- 250ml
- 500ml
- 1000ml

Innovative Technology :

- SteriPort bottles for IV fluid are manufactured with ISBM Technology using polypropylene as raw material



Therapeutic Segments	Products
Anti - fungal	Fluconazole
Anti - Pyretic	Paracetamol
Diuretics	Mannitol IV
Anti - Biotic	Linezolid
Quinolones	Ciprofloxacin, Levofloxacin, Gemifloxacin and Moxifloxacin
Anti - Anaerobic	Metronidazole Tinidazole

Product Focus :

- Injectables
- Ophthalmic
- Respiratory

Fill Volume Range :

- 2ml to 100ml

Technology :


- Aseptic Blow-Fill- Seal (ABFS) & Injection Stretch Blow Moulding (ISBM) technology


Notable Formulations:

- Ciprofloxacin
- Metronidazole
- Ofloxacin
- Paracetamol
- Fluconazole

Packaging Options:


- Large Volume Parenterals (LVPs)
- Small Volume Parenterals (SVPs)





Key Products :

- Lidocaine
- Potassium Chloride
- Magnesium Sulphate
- Calcium Chloride
- Calcium Gluconate



Injectables Portfolio



Diluents Overview




Pack Sizes :

- Offered in 5 ml & 10 ml

Products :

- Sterile Water for Injection (WFI)
- Normal Saline WFI





Therapeutic segments	Product
Ophthalmic (FFS)	Ciprofloxacin Ophthalmic Solution U.S.P. (0.3 % w/v)
Ophthalmic (FFS)	Timolol Maleate Eye Drops B.P. (0.5 % w/v & 0.25 % w/v)
Ophthalmic (FFS)	Gentamicin Eye Drops B.P. (0.3% w/v)
Ophthalmic (FFS)	Gentamicin Sulphate (0.3 % base) & Dexamethasone (0.1% w/v) Eye/Ear Drops
Ophthalmic (FFS)	Tobramycin (0.3% w/v) + Dexamethasone (0.1% w/v) Eye Drops
Ophthalmic (3 Piece)	Carboxymethyl Cellulose Sodium Eye Drops (0.5 % w/v)
Ophthalmic (3 Piece)	Hypromellose Eye Drops (0.5v% w/v)
Ophthalmic (3 Piece)	Sodium Hyaluronate 0.3% w/v Eye Drops



Dosage Form :

- 5ml & 10ml



Applications :

- Including treatment for Infections, Glaucoma, Inflammation



Package Options :

- Form Fill Seal (FFS) Pack
- Three-Piece Conventional Pack





Dosage Form :

- Available in 2.5ml



Applications :

- Administered through nebulizers for the treatment of lungs affected by Asthma or Bronchiectasis.

Key Product :

- Budesonide Respiratory Suspension
- Salbutamol Respiratory Solution
- Salbutamol & Ipratropium Bromide Respiratory Solution
- Levosalbutamol Inhalation solution
- Levosalbutamol and Ipratropium Respiratory Solution





Product Types :

- OTC Eye Lubricants
- Wound Cleaning Solutions



Dosage Forms :

- Available in 5ml, 10 ml & 20 ml



Product :

- Sodium Chloride Eye Wash
- Wound Cleaning



LVP: Large Volume Parenteral

SVP: Small Volume Parenteral

ABFS: Aseptic Blow Fill Seal

ISBM: Injection Stretch-Blow Moulding

WFI: Water For Injection

SWFI: Sterile Water For Injection

WHO-GMP: WHO - Good Manufacturing Practices

PICs: Pharmaceutical Inspection Co-operation Scheme

ISO: International Organization for Standardization

SAL: Sterility Assurance Level

OTC: Over-the-Counter

ESG: Environmental, Social, and Governance



Amanta Healthcare Ltd.
8th Floor, Shaligram Corporates,
C. J Marg, Ambli, Ahmedabad 380058 Gujarat, India.
Telephone: 079 6777 7600
Email Id: cs@amanta.co.in
Website: www.amanta.co.in

Investor Relations
Go India Advisors

Name: Ms. Soumya Chhajer

Tel: +91-8619707750

Email: soumya@goindiaadvisors.com

Name: Ms. Shrutee Barve

Tel: +91-9892517329

Email: shrutee@goindiaadvisors.com